Clinical Trial

Short-Term Safety and Performance of Two Wound Dressings Evaluation

Study acronym: POLTX_Fiber
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Chronic wounds, including venous leg ulcers, diabetic foot ulcers, and pressure ulcers, are defined as wounds that fail to heal within 4-8 weeks despite appropriate care. They represent a significant health burden due to prolonged healing, risk of infection, recurrence, and impact on quality of life and healthcare costs. Their development is multifactorial and often linked to vascular impairments, which reduce oxygen and nutrient supply. This leads to impaired tissue repair, persistent inflammation, and increased susceptibility to infection. Standard treatment includes wound debridement, infection control, maintaining a moist environment, and managing pain and exudate. POLTX\_Fiber is an absorbent gelling fiber dressing designed to improve moisture balance, manage exudate, and reduce bacterial load, with established safety and CE marking. A post-market clinical follow-up study will compare POLTX\_Fiber with Suprasorb® Liquacel Pro over a 30-day period in an outpatient setting. The study evaluates wound healing, infection status, usability, pain, and patient satisfaction. It is conducted in accordance with EU and Swiss regulations, ensures qualified investigators, and considers sex and gender differences in the analysis.
Trial Details
NCT Number NCT07576322
Lead Sponsor Sebastian Probst
Collaborators: eHnv Hospital, University Hospital, Geneva, CHUV, Lausanne University Hospitals, Switzerland
Conditions Chronic Wound Care, Local Infection, Safety
Enrollment 60 participants
Start Date 2026-06-15
Primary Completion 2027-06-14 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-08